3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
6
Prostatic Neoplasms
3
Neoplasms
3
Motor Activity
3
Pancreatic Neoplasms
2
Overweight
2
Obesity
2
Malnutrition
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Weight Loss
1
Urinary Bladder Neoplasms
1
Taste Disorders
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcopenia
1
Rectal Neoplasms
1
Patient Compliance
1
Ovarian Neoplasms
1
Obesity-Related Malignant Neoplasm
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Metabolic Diseases
1
Lymphoma
1
Locally Advanced Head and Neck Squamous Cell Carcinoma
1
Hypertension
1
Hypercholesterolemia
1
Heart Failure
1
Heart Diseases
1
Esophageal Neoplasms
1
Interventions
lutetium Lu 177 dotatate
20
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
amino-acid, glucose, and electrolyte solution
4
Capecitabine
4
olaparib
3
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Nutrition Assessment
×
1 year
×
Clear all
No trials found.